INEGYT Is Superior To Simvastatin In Reducing Key Risk Markers Of Atherosclerosis - Confirmed
Christie Ballantyne, M.D., director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, U.S.A., and lead investigator of one of the clinical studies noted: "In clinical practice, both CRP, which measures inflammation, and apo-B, which measures the total number of atherogenic particles, are predictors of cardiovascular risk. Previous research has demonstrated that INEGY, which is the first single tablet to treat two sources of cholesterol - both production of cholesterol in the liver and absorption of cholesterol in the intestine - is more effective in reducing overall LDL-cholesterol levels than a statin alone. The additional benefit in lowering both CRP and apo-B shown in these two studies points to dual inhibition with INEGY as an important treatment option for hypercholesterolemia patients."
INEGY was more effective than simvastatin alone at reducing lipoprotein subfractions
This analysis compared the effects of ezetimibe alone, simvastatin alone and INEGY (single tablet) on apolipoprotein-B containing lipoprotein subfractions.[1] Lipoproteins are protein compounds that are used to transport lipids around the body in the blood stream and apolipoprotein is the protein component of lipoprotein. Apo-B is particularly significant as it is the major apolipoprotein found in low density lipoprotein cholesterol (LDL-C) or 'bad' cholesterol. In this study, the primary analysis of which was median percent change in subfraction cholesterol for INEGY versus ezetimibe alone and simvastatin alone, 1528 patients with hypercholesterolemia were randomized to receive either INEGY (various dosing combinations) or simvastatin (various mg doses). Cholesterol associated with lipoprotein subclasses was quantified by the vertical autoprofile II method. Results found that INEGY produced significant reductions in very-low-density lipoprotein cholesterol (VLDL-C), intermediate-density lipoprotein cholesterol (IDL-C) and LDL-C versus ezetimibe alone or simvastatin alone.
This trial supports previous research into the relationship between apo-B and apoprotein A-1 (or Apo A-1, the principle apolipoprotein found in high density lipoprotein or 'good' cholesterol) and heart disease. Results from the INTERHEART trial, involving more than 29,000 people, show that the two most important predictors of heart attack risk are cigarette smoking and an abnormal ratio of apo-B to apo A-1, which together predicted two thirds of the global risk of heart attack.[3]
INEGY provided additional incremental CRP and LDL-C lowering beyond that achieved with simvastatin alone.
This post hoc analysis pooled data from three similar randomized, placebo controlled, double blind studies and was conducted to evaluate the CRP lowering effects of ezetimibe, simvastatin and INEGY.[2]
The efficacy of ezetimibe and INEGY was monitored in terms of percent changes from baseline in CRP and LDL-C levels and the percentage of patients achieving defined single and dual LDL-C (
INEGYT este superior Simvastatin-cheie în reducerea riscului markeri de aterosclerozã - Confirmat - INEGYT Is Superior To Simvastatin In Reducing Key Risk Markers Of Atherosclerosis - Confirmed - articole medicale engleza - startsanatate